上海医药下属公司富马酸福莫特罗吸入溶液获批生产

财中社
09 Jun

  6月9日,上海医药(601607/02607)发布公告,近日,公司下属上海信谊金朱药业有限公司的富马酸福莫特罗吸入溶液获得国家药品监督管理局颁发的药品注册证书,批准生产。

  该药品主要用于慢性阻塞性肺部疾病患者的气道阻塞维持治疗,每日使用两次,具备长期用药的特点。公司已为该药品投入研发费用约441万元。根据数据库信息,2024年中国大陆医院采购富马酸福莫特罗吸入溶液的金额为4.62亿元。

  2025年一季度,上海医药实现收入707.63亿元,归母净利润13.33亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10